Image For Activity Cover
Appropriate Interpretation of Urine Drug Screen Results
Overview



Presenter(s): Emily E. Leppien, PharmD, BCPS, BCPP

Target Audience: This activity is designed for pharmacists. This activity is accredited for pharmacists.

Webinar Description: Controlled substances, including opioids, benzodiazepines and medical cannabis, are commonly prescribed for treatment of chronic pain. Urine drug screens (UDS) are often used in clinical practice to test for the presence of prescribed drugs in an effort to monitor compliance. This application-based webinar will provide participants the opportunity to further their ability to appropriately interpret UDS results through review of real-life patient case scenarios.

Educational Objectives:

  • List causes that may lead to unexpected UDS results, specifically false positives and negatives.
  • Discuss how opioid and benzodiazepine metabolism impacts UDS results.
  • Interpret a UDS reading based on patient history and reported results.
  • Recommend appropriate monitoring based on patient history and UDS results.
Certificate Instructions

Requirements for successful activity completion:

In order to successfully complete this activity and obtain your Certificate, you will be required to:

  1. Course Content: Complete the pre-reflection question and view the recorded presentation.

  2. Click Survey and answer the questions to the best of your ability.
    Upon completion of this survey, it will unlock and allow you to proceed to the final course evaluation. 


  3. Click Evaluation to complete the final PCSS course evaluation.

  4. Following your completion of the evaluation, you will have access to your Certificate of Completion. 

Note: This archive webinar is not designated for AMA PRA Category 1 Credit™.

Summary
Availability: On-Demand
Access expires on 03/13/2026
Cost: FREE
Credit Offered:
1 Attendance Credit
Recommended
 
The content on this site is intended solely to inform and educate medical professionals. This site shall not be used for medical advice and is not a substitute for the advice or treatment of a qualified medical professional.



Funding for this initiative was made possible (in part) by grant nos. 1H79TI086770 and 1H79TI085588 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

 
PCSS-MOUD
pcssNow.org
pcss@aaap.org
For Buprenorphine Training Inquiries, email PCSS-MOUD.

ORN
opioidresponsenetwork.org

Powered By